|Day Low/High||174.61 / 176.85|
|52 Wk Low/High||130.09 / 176.64|
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months
The once-mighty biotech has fallen, but entry opportunities will surface.
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
Novel Treatment Administered Intravenously Would put Delivery of Important Therapy in the Hands of the Healthcare Provider
Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo
Amgen's (AMGN) last run to highs stalled out, but the stock could still push through the old highs, according to TheStreet's Chris Versace and Bob Lang.
The shares have some power and legs to get up and through old highs.
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Drug companies like Merck, Pfizer and Johnson & Johnson are spending big bucks on the opposition of Proposition 61.
Shares of Amgen are under pressure today. Here's how to trade it from here.
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Investors have been cautious on Amgen, but the company has a strong pipeline of drugs in development.
Amgen (AMGN) and the French pharmaceutical company Servier announced today that they'd extended a partnership on development and commercialization of their chronic heart failure drug.
Servier Provides Notice to Exercise Commercialization Option in Europe and Commonwealth of Independent States, Including Russia
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy